Royalty Report: Drugs, Pain, Pharmaceuticals – Collection: 4717

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Pain
  • Pharmaceuticals
  • Biotechnology
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4717

License Grant
Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses.
License Property
The license is for the development and commercialization of non-injectable Dex (Dexmedetomidine) for use in the treatment of pain (including post-operative pain) in humans in any dosage form for transdermal, transmucosal (including sublingual and intranasal), topical, enteral or pulmonary (inhalational) delivery, the Licensed Dosage Forms, but specifically excluding delivery vehicles for administration by injection or infusion.

Dex is in a class of drugs called alpha-2 adrenergic agonists, which produce their effects by selectively activating the alpha-2 adrenergic receptors in the body and produce a broad range of effects depending on the specific drug and the alpha-receptors it activates, including anti-hypertensive, analgesic and sedative effects. In particular, Dex has demonstrated sedative, analgesic and anxiolytic properties in multiple preclinical and clinical studies, including the new drug application, or NDA, studies for Precedex®.

5217718 & 5124157: TRANSDERMAL ADMINISTRATION OF DEXMEDETOMIDINE – Method and device for administering dexmedetomidine transdermally

Field of Use
Under the Dexmedetomidine License Agreement, they were granted an exclusive license under Licensor Know-How and certain Patents to commercialize products in the territory.

“Field” means the treatment of pain in humans, including mild, moderate, or severe acute and chronic pain, alone or as an adjunct.

IPSCIO Record ID: 3563

License Grant
Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses.

They entered into an  license agreement for the development and commercialization of Fado (Fadolmidine) for use as a human therapeutic, in any dosage form.

License Property
Fado is in a class of drugs called alpha-2 adrenergic agonists, which produce their effects by selectively activating the alpha-2 adrenergic receptors in the body and produce a broad range of effects depending on the specific drug and the alpha-receptors it activates, including anti-hypertensive, analgesic and sedative effects. Fado shows promise in neuropathic pain. It does not cross the blood brain barrier and this accounts for the targeting of Fado use for either IT administration for pain or anesthesia, or potentially for topical use to treat pain associated with regional nerve pain from underlying nerve damage, also called “neuropathies.”

U.S patent numbers (6313311; 7759496; 6479530; 6495584)

Field of Use
Fado is a product candidate to be used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Licensee intends to pursue as a topical product for local application to treat serious pain associated with neuropathies, especially of the lower extremities, which can occur in diabetic patients.

IPSCIO Record ID: 26293

License Grant
The Licensee entered into a collaborative arrangement with a German Licensor.  The collaboration is focused on the development of drugs for a single therapeutic application-pain-but may involve multiple receptor families.  The Licensor is collaborating on the Alpha-2  Adrenergic Program to develop drugs for the alleviation of pain.
Field of Use
The rights granted apply to any human  pharmaceutical  product for  alleviating pain.

IPSCIO Record ID: 266813

License Grant
The Licensor of France grants an exclusive license, with right to sublicense, under the Licensed Rights, lo import, use, sell and offer for sale, make and have made, Products in the Territory.

Licensor also grants the right to make and have made the Products outside the Territory for use within the Territory.

License Property
Injectible APAP Product means any parenterally administered dosage form of paracetamol or propacetamol, or any Derivative thereof, whether alone or in combination with one or more other drugs.

The term Product shall mean any parenterally administered dosage form containing paracetamol.

Paracetamol, also known as acetaminophen and APAP, is a medication used to treat pain and fever. It is typically used for mild to moderate pain relief. There is mixed evidence for its use to relieve fever in children. It is often sold in combination with other medications, such as in many cold medications.

Field of Use
Competing Product means any one or more non-opiate analgesic parenterally-administered liquid solution products, in a stable and readily injectible form for the treatment of post-operative pain.

IPSCIO Record ID: 27649

License Grant
Licensor grants an exclusive license, with the right to grant sublicenses under the licensed technology to make, use, have made, sell, offer for sale, import and export products.

Licensor grants a license to use the house marks in connection with the commercialization of the products.

License Property
The licensed technology is US patent 6926907 and filed patent serial no. 11/129,320, pharmaceutical compositions for the coordinated delivery of NSAIDs.

NSAID means any non-steroidal anti-inflammatory drug, the primary mechanism of action of which is inhibition of cyclooxygenase, but excluding acetyl salicylic acid.

Field of Use
The field of use is the treatment of human diseases and conditions by means of a pharmaceutical product.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.